active ingredient semaglutide in weight loss drug Wegovy may help treat type of fatty liver disease: Study Semaglutide | C187H291N45O59 | CID

58 Franceschi et al in 2018 and Li et al in 2021 outlined the hallmarks of aging, which include: 1) genomic instability, 2) reduced telomere length, 3) epigenetic influences, 4) loss of proteostasis or macromolecular damage 5) deregulated nutrient sensing and metabolic signaling pathways, 6) cellular senescence, 7) stem cell exhaustion, 8) stress and mitochondrial dysfunction and 9) altered intercellular communication

Furthermore, their combined glucose-lowering and weight-reduction effects reduce the risk of AF onset and recurrence and further contribute to the regulation of AF triggers through metabolic modulation

In this regard, GLP-1RAs can provide the protection against VSMC senescence via increasing the nuclear factor erythroid 2-related factor 2 (Nrf2) activity [122]

Heres the caveat: while the animal data is overwhelmingly positive, human studies are extremely limited